Retatrutide

Retatrutide is a synthetic lipidated peptide and the first-in-class GLP-1 / GIP / Glucagon receptor triple agonist under clinical development by Eli Lilly (development code LY3437943). By simultaneously activating all three incretin-related receptors, Retatrutide delivers significantly greater weight loss and glycemic control than single or dual agonists - phase 2 trials reported mean body-weight reductions exceeding 24 % in participants with obesity at 48 weeks.

• GLP-1 receptor agonism - suppresses appetite, slows gastric emptying, enhances insulin secretion.
• GIP receptor agonism - improves insulin sensitivity and lipid handling.
• Glucagon receptor agonism - increases energy expenditure and hepatic lipid oxidation.

- Appearance: White to off-white lyophilized powder
- Purity (HPLC): ≥ 99.0 %
- Counter-ion: Acetate / salt-free on request
- Storage: -20 °C, protected from light and moisture
- Packaging: 1 mg / 10 mg / 100 mg / 1 g research packs; bulk ≥ 1 kg on request

- Full Certificate of Analysis (HPLC, MS, NMR, amino-acid analysis)
- Residual solvent profile per ICH Q3C
- Endotoxin, microbial and bioburden reports available
- DMF support and custom synthesis for downstream filing partners

For research, development and further manufacturing use only. Not intended for direct human therapeutic administration unless covered by an applicable regulatory filing.

Hot Tags: Retatrutide, China Retatrutide suppliers, amphotericin cost, finerenone uses, oseltamivir phosphate 6 mg, tacrolimus 0 1 price, teicoplanin uses, use of zinc sulphate in agriculture